BOTHELL, Wash.--(BUSINESS WIRE)--Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that it has completed enrollment in the Phase 3 pivotal trial of its lead oncology product candidate, TOCOSOL® Paclitaxel, in women with metastatic breast cancer. Formulated with the Company’s proprietary vitamin E-based emulsion TOCOSOL technology, TOCOSOL Paclitaxel is a new formulation of the widely prescribed anti-cancer drug, paclitaxel, which is a member of the taxane group of chemotherapy drugs. Sonus expects data from the TOCOSOL Paclitaxel Phase 3 trial to be available in the third quarter of 2007, with submission of a New Drug Application (NDA) targeted for the end of 2007.
